| pubmed-article:19533660 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19533660 | lifeskim:mentions | umls-concept:C1377665 | lld:lifeskim |
| pubmed-article:19533660 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:19533660 | lifeskim:mentions | umls-concept:C1538577 | lld:lifeskim |
| pubmed-article:19533660 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:19533660 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:19533660 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:19533660 | pubmed:dateCreated | 2009-10-19 | lld:pubmed |
| pubmed-article:19533660 | pubmed:abstractText | Despite advances in therapy, outcome in many high-grade pediatric central nervous system (CNS) tumors remains poor. The focus of neuro-oncology research has thus turned towards identifying novel therapeutic targets. Poly(ADP-ribose) polymerase-1 (PARP1) is a DNA repair protein that has been studied in a variety of malignancies and may interfere with therapy-induced DNA damage, however expression in pediatric CNS tumors is unknown. | lld:pubmed |
| pubmed-article:19533660 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19533660 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19533660 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19533660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19533660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19533660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19533660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19533660 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19533660 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19533660 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:19533660 | pubmed:issn | 1545-5017 | lld:pubmed |
| pubmed-article:19533660 | pubmed:author | pubmed-author:Kleinschmidt-... | lld:pubmed |
| pubmed-article:19533660 | pubmed:author | pubmed-author:ForemanNichol... | lld:pubmed |
| pubmed-article:19533660 | pubmed:author | pubmed-author:LiuArthur KAK | lld:pubmed |
| pubmed-article:19533660 | pubmed:author | pubmed-author:GoreLiaL | lld:pubmed |
| pubmed-article:19533660 | pubmed:author | pubmed-author:DonsonAndrew... | lld:pubmed |
| pubmed-article:19533660 | pubmed:author | pubmed-author:BartonValerie... | lld:pubmed |
| pubmed-article:19533660 | pubmed:copyrightInfo | (c) 2009 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:19533660 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19533660 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19533660 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:19533660 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19533660 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19533660 | pubmed:pagination | 1227-30 | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:meshHeading | pubmed-meshheading:19533660... | lld:pubmed |
| pubmed-article:19533660 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19533660 | pubmed:articleTitle | PARP1 expression in pediatric central nervous system tumors. | lld:pubmed |
| pubmed-article:19533660 | pubmed:affiliation | Department of Pediatrics, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA. valerie.barton@ucdenver.edu | lld:pubmed |
| pubmed-article:19533660 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19533660 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
